Pioneering life-changing therapies through innovative science

Noxopharm® Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, plus improvements to mRNA vaccines.
We have two innovative technology platforms – Sofra™ (mRNA, inflammation and autoimmunity) and Chroma™ (oncology), which provide the basis for active development of a growing pipeline of new proprietary drugs.


Chroma™ is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment.
The Sofra™ technology platform has a pipeline of new proprietary drugs based on oligonucleotides, the building blocks of DNA or RNA, with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases.
Veyonda® is Noxopharm’s clinical drug candidate, currently in a phase 1 investigator-initiated clinical trial for the treatment of cancer in combination with immunotherapy.
My Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis rutrum sapien non ornare sagittis. Fusce quis dignissim felis. Pellentesque iaculis nisl et est ultricies, id mollis lorem volutpat. Praesent nec nunc vel quam facilisis scelerisque a ut orci. Sed sed enim vestibulum ex commodo venenatis vitae in mi. In eu velit sed nunc euismod tempor ac at odio. Mauris sit amet mi ac turpis rutrum congue sit amet id nunc.

"We are a highly dedicated group of experts who are dedicated to tackling some of the biggest challenges in medicine. We are leveraging specialist in-house capabilities and strategic partnerships with leading researchers to address various types of cancer and autoimmune diseases such as lupus, as well as developing technologies that will improve the effectiveness of mRNA vaccines. Our strategy is to deploy innovative approaches to developing new drugs, principally through research and development programs that explore the very building blocks of new treatments - the molecules and compounds that may one day save lives." 

Dr Gisela Mautner, CEO




Latest ASX Announcements